Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, presented a poster at IMMUNOLOGY2023™, the American Association of Immunologists (AAI) Annual Meeting, titled: “Chimeric Cytokine Receptor Provides IL-2 Signaling for Engineered Regulatory T Cell Therapy.”
Interleukin-2 (IL-2), a cytokine signaling molecule in the immune system, is essential for Treg survival, expansion, phenotypic stability, and suppressive function. As Tregs do not produce IL-2, they are dependent on external sources for the molecule, limiting the persistence and durability of Treg cell therapies in tissues with no or limited IL-2 availability in the microenvironment. The study presented at IMMUNOLOGY2023 assessed the Company’s development of engineered Treg cells containing a chimeric cytokine receptor that provides an IL-2 signal, in order to address this challenge. Results of the study demonstrated the successful generation of Tregs with self-sufficient IL-2 signaling for clinical use in low IL-2 environments.
AAI is an international scientific society dedicated to furthering the study of immunology. The largest annual immunology event worldwide, the AAI Annual Meeting is where leading researchers come to learn the latest in their field.